Loss of TR4 Orphan Nuclear Receptor Reduces Phosphoenolpyruvate Carboxykinase-Mediated Gluconeogenesis

  1. Ning-Chun Liu1,
  2. Wen-Jye Lin1,
  3. Eungseok Kim1,,2,
  4. Loretta L. Collins1,
  5. Hung-Yun Lin1,
  6. I-Chen Yu1,
  7. Janet D. Sparks1,
  8. Lu-Min Chen1,,3,
  9. Yi-Fen Lee (yifen_lee{at}urmc.rochester.edu)1 and
  10. Chawnshang Chang (chang{at}urmc.rochester.edu)1
  1. From the 1George Whipple Laboratory for Cancer Research, Department of Pathology, Urology, Radiation Oncology and the Cancer Center, University of Rochester, Rochester, New York
  2. 2Department of Biological Sciences, Chonnam National University, Gwangju, Korea; and the
  3. 3Department of OB/GYN, China Medical University/Hospital, Taichung, Taiwan

    Abstract

    Objective: Regulation of phosphoenolpyruvate carboxykinase (PEPCK), the key gene in gluconeogenesis, is critical for glucose homeostasis in response to quick nutritional depletion and/or hormonal alteration.

    Research Design and Methods and Results: Here we identified the orphan nuclear receptor 4 (TR4) as a key PEPCK regulator modulating PEPCK gene via a transcriptional mechanism. TR4 transactivates the 490-bp PEPCK promoter-containing luciferase reporter gene activity by direct binding to the TR4 responsive element (TR4RE) located at -451 to -439 in the promoter region. The binding to the TR4RE was confirmed by electrophoretic mobility shift and chromatin immunoprecipitation assays. Eliminating TR4 via knockout and RNA interference in hepatocytes significantly reduced the PEPCK gene expression and glucose production in response to glucose depletion. In contrast, ectopic expression of TR4 increased PEPCK gene expression and hepatic glucose production in human and mouse hepatoma cells. Mice lacking TR4 also display reduction of PEPCK expression with impaired gluconeogenesis.

    Conclusion: Together, both in vitro and in vivo data demonstrate the identification of a new pathway, TR4 → PEPCK → gluconeogenesis → blood glucose, which may allow us to modulate metabolic programs via the control of a new key player, TR4, a member of the nuclear receptor superfamily.

    Footnotes

      • Received March 19, 2007.
      • Accepted August 31, 2007.